Susquehanna International Group
GRCE

Susquehanna International Group’s Grace Therapeutics GRCE Stock Holding History

Susquehanna International Group’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$234K Buy
+50,600
New +$199K ﹤0.01% 11394

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Susquehanna International Group's GRCE Position: Q3 2024 in Review

Susquehanna International Group sold out of Grace Therapeutics (GRCE) in Q3 2024, closing a stake of 37,793 shares — an estimated $113K sold.

Susquehanna International Group first reported a position in GRCE in Q4 2014 and held it in 6 quarters. The position peaked at $528K in Q4 2017. 12 funds tracked by Wall St. Rank hold GRCE as of Q3 2024.

  • Susquehanna International Group reported no remaining Grace Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 37,793 Grace Therapeutics shares in Q3 2024, an estimated $113K.
  • Susquehanna International Group first reported a position in Grace Therapeutics in Q4 2014 and held it in 6 quarters.
  • Susquehanna International Group's Grace Therapeutics position peaked at $528K in Q4 2017.
  • 12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.